Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29604716 | 1.00 | MAP3K14 (0.40) | MAP3K14SMN1; SMN2RAB9ANPC1OPRM1 | |
| SCHEMBL29605779 | 1.00 | MAP3K14 (0.40) | MAP3K14SMN1; SMN2RAB9ANPC1OPRM1 | |
| SCHEMBL29605401 | 0.87 | MAP3K14 (0.41) | MAP3K14SMN1; SMN2RAB9ANPC1OPRM1 | |
| SCHEMBL29605217 | 0.78 | MAP3K14 (0.50) | MAP3K14SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL29604666 | 0.78 | MAP3K14 (0.48) | MAP3K14SMN1; SMN2RAB9ALMNAMAPT | |
| SCHEMBL29605715 | 0.75 | CDK1 (0.45) | MAP3K14 | |
| SCHEMBL26969451 | 0.75 | CDK1 (0.45) | MAP3K14 | |
| SCHEMBL29605188 | 0.75 | CDK1 (0.45) | MAP3K14 | |
| SCHEMBL29604849 | 0.74 | MAP3K14 (0.39) | MAP3K14RAB9AMAPT | |
| SCHEMBL26969483 | 0.74 | MAP3K14 (0.39) | MAP3K14RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416256-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARAMCEUTICA NV (BE) | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416256-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, NFRKB | MAP3K14 28/4885SMN1; SMN2 4654/4885RAB9A 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.